Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 10, 2008

View Archived Issues

Novel immunosuppressants reported in Daiichi Sankyo patent

Novel anticancer agents revealed in patent literature

Study examines reduced calcineurin inhibitor doses in renal transplant patients

Studies examine activity of LY-686017 in alcoholism, social anxiety and IBS

New treatment options for inflammatory and autoimmune diseases claimed in recent patents

Update on development of hepatitis C protease inhibitor telaprevir

Alseres completes enrollment in phase I/IIa clinical trial of Cethrin and plans phase IIb trial

NicOx and Pfizer extend ophthalmology collaboration agreement

Ortho-McNeil puts APD-668 for type 2 diabetes on hold, advances other GDIR agonist

Baxter initiates preclinical programs for recombinant factor IX proteins for hemophilia B

Tacere signs collaboration and license agreement with Pfizer for TT-033 for HCV

Phase II study of Hemospan for chronic critical limb ischemia begins

Evotec' EVT-302 for smoking cessation well tolerated in phase I study

FDA approves Medarex's IND application for anti-CD70 antibody MDX-1411

ZymoGenetics initiates phase II trial of IL-21 with Nexavar for renal cell cancer

Incyte reports positive clinical results from studies of INCB-18424 and INCB-13739

COL4A1, candidate gene for newly described systemic basement-membrane syndrome

Phase III study of oxybutynin topical gel for OAB meets primary and secondary endpoints

Sirtris reports positive results from phase Ib study of SRT-501 for type 2 diabetes

Neurogen reports results of follow-up component of phase I study of NGD-4715 for obesity

Ambien CR tablets CIV improve chronic insomnia in GAD patients

Therapeutic potential of GLS1 inhibition in schizophrenia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...